Clinical Genomics at The Royal Marsden

What is clinical genomics?

The Royal Marsden, together with the Institute of Cancer Research, is one of the largest comprehensive cancer centres in Europe. The Clinical Genomics service is a highly experienced, multi-disciplinary team of dedicated clinical and research scientists, offering a range of genomic testing specific to oncology.

Identifies genetic changes in individual cancers

Why choose us?

Using a variety of specialised techniques; more comprehensive diagnostics and monitoring is achieved

Personalised and improved treatments and outcomes for patients.

We strive to provide a high-quality clinical genomics service, translating our scientific knowledge into diagnostic excellence, improving cancer treatment and care.

Our innovative cancer testing includes Next Generation Sequencing (NGS) gene panels for solid tumours and haematological malignancies, and collaboration with research teams to design bespoke panels and whole exome sequencing.

The Royal Marsden is the designated cancer testing laboratory for the North Thames Genomics Laboratory Hub (GLH). Our scientific expertise allows us to deliver cutting-edge technology and provide the interpretation of complex genomic data, and our academic excellence in genomics and translational medicine can advance clinical practice and promote clinical innovation.

Bespoke service

Personalised care to improve treatments and outcomes for cancer patients

Bespoke NGS panels, as directed by oncologists, are specific to the patient based on their clinical symptoms and differential diagnosis.

Our knowledgeable staff are readily available to discuss the genomic results in a clear and understandable way.

Innovative testing

Working closely with oncology experts, we can use innovative genomic testing to bring personalised treatments to patients sooner

As early adopters of new genomic testing, we are leading the way in applying ground-breaking technologies to cancer treatment and care.

Our pan cancer approach allows us to detect rare genetic changes in the tumour, which supports diagnosis, prognosis, disease monitoring and predictive response to therapies.

Our large trial portfolio and extensive repertoire of genomic cancer tests results in rapid and accurate profiling of solid tumours and haematological malignancies.

Flexible offering

Comprehensive tumour profiling gives patients access to a wider range of treatment options

The range of specialised genomic cancer tests provide a comprehensive overview of the tumour profile to identify diagnostic markers, treatment targets and potential resistant mutations.

Sequencing results can be revisited and reinterpreted without the need for additional samples to be taken, and can be easily adapted to the clinical setting.

World leading experts

Our Next Generation Sequencing (NGS) panels are designed by oncologists for oncologists

Our world leading experts are at the forefront of research and diagnostic, applying new technologies that contribute to the acceleration of clinical genomics in oncology.

Our expertise is utilised in our molecular tumour boards, where oncologists and scientists come together to interpret results and direct treatment strategies personalised to the patient.

Rapid translation

We have a rapid pipeline to translate genomic research to the clinical setting

Our world-class healthcare and academic partnership accelerates our genomic research from the laboratory to the clinic, offering a personalised approach to treatment for cancer patients.

Our proven track record working with pharmaceutical and Biotech companies provide the opportunities for new collaborations to introduce advanced technologies into clinical use.